Browsing Tag
IDEAYA Biosciences
2 posts
How the OptimUM-02 trial timeline may influence investor and clinical sentiment in ocular oncology
IDEAYA Biosciences nears darovasertib data. Find out how this Phase 3 readout could reshape metastatic uveal melanoma treatment today.
March 25, 2026
GSK walks away from IDEAYA cancer assets: What went wrong with synthetic lethality?
GSK ends its partnership with IDEAYA on two oncology assets. Find out what this means for IDEAYA’s pipeline, stock sentiment, and future partnerships.
December 6, 2025